These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24912253)

  • 41. Effectiveness of omalizumab in non-allergic severe asthma.
    Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
    J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
    J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New guidelines and new therapy options in severe asthma].
    Einecke D
    MMW Fortschr Med; 2016 May; 158(9):18-9. PubMed ID: 27155682
    [No Abstract]   [Full Text] [Related]  

  • 44. Pediatric Asthma--do we need more innovation for treatment?
    Riedler J
    Pediatr Allergy Immunol; 2014 Feb; 25(1):19-20. PubMed ID: 24588482
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of omalizumab treatment in a baker with occupational asthma.
    Pérez Pimiento A; Bueso Fernández A; García Loria J; Rodríguez Cabreros MI; Mosquera MR; García Cubero A
    J Investig Allergol Clin Immunol; 2008; 18(6):490-1. PubMed ID: 19123449
    [No Abstract]   [Full Text] [Related]  

  • 46. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting IgE in asthma.
    Kuhl K; Hanania NA
    Curr Opin Pulm Med; 2012 Jan; 18(1):1-5. PubMed ID: 22139745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
    Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
    Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 50. Reslizumab (Cinqair) for Eosinophilic Asthma.
    Bondar A; Carr M
    Am Fam Physician; 2017 Nov; 96(10):671-672. PubMed ID: 29431392
    [No Abstract]   [Full Text] [Related]  

  • 51. [Monoclonal antibodies for severe asthma (review)].
    Solèr M
    Ther Umsch; 2019 Nov; 76(6):317-321. PubMed ID: 31762416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A case of an asthma patient receiving omalizumab during pregnancy].
    Hirashima J; Hojo M; Iikura M; Hiraishi Y; Nakamichi S; Sugiyama H; Kobayashi N; Kudo K
    Arerugi; 2012 Nov; 61(11):1683-7. PubMed ID: 23328225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drugs to avoid during pregnancy: omalizumab and montelukast, too many uncertainties.
    Prescrire Int; 2014 Feb; 23(146):51. PubMed ID: 24669391
    [No Abstract]   [Full Text] [Related]  

  • 54. Does anti-IgE therapy help in asthma? Efficacy and controversies.
    Avila PC
    Annu Rev Med; 2007; 58():185-203. PubMed ID: 17059361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 56. Links between allergic rhinitis and asthma.
    Li J; Wang HY; Zhang CQ; Sun BQ; Zhong NS
    Chin Med J (Engl); 2006 Apr; 119(8):676-83. PubMed ID: 16635413
    [No Abstract]   [Full Text] [Related]  

  • 57. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
    Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
    Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel therapies in asthma: leukotriene antagonists, biologic agents, and beyond.
    Papierniak ES; Lowenthal DT; Harman E
    Am J Ther; 2013 Jan; 20(1):79-103. PubMed ID: 23299231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.